Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

Doki0926 Oct. 14 at 7:48 PM

$CRVO abnormal, brutal, total shit

0 · Reply

Doki0926 Oct. 14 at 7:47 PM

$CRVO it will never go back

0 · Reply

Shelz912 Oct. 14 at 7:13 PM

$CRVO This drug is an anti-inflammatory but not for arthritis but it has the potential. Maybe one day.

0 · Reply

BPler Oct. 14 at 5:29 PM

$CRVO

0 · Reply

Pharoh42 Oct. 13 at 9:24 PM

$CRVO I have now 10k shares with avg $10.24 Can we get there by earning?

1 · Reply

Doki0926 Oct. 13 at 7:11 PM

$CRVO WHAT WILL BE THE END FOR THIS FUCKING PIECE OF SHIT

1 · Reply

Disinformation_Consumer Oct. 10 at 8:24 PM

$CRVO lmao CRVO actually fell less than NVidia and Tesla today during trading hours. What a shitshow all around.

1 · Reply

Enzo4u Oct. 10 at 5:09 PM

$CRVO agreed, they will do some offering and tank this further

0 · Reply

Stu_padasso Oct. 10 at 5:01 PM

$CRVO fucking garbage

1 · Reply

Doki0926 Oct. 10 at 4:18 PM

$CRVO 😂😂😂😂

0 · Reply

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 6 days ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 12 days ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 27 days ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 5 weeks ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 2 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 2 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 3 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 5 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 7 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 7 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 7 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 7 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 9 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 10 months ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 11 months ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 11 months ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 11 months ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 11 months ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 11 months ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 1 year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 16, 2023, 1:58 PM EDT - 2 years ago

CervoMed Announces Completion of Merger with EIP Pharma

Aug 15, 2023, 4:01 PM EDT - 2 years ago

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Apr 3, 2023, 2:13 PM EDT - 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN

EXR

Doki0926 Oct. 14 at 7:48 PM

$CRVO abnormal, brutal, total shit

0 · Reply

Doki0926 Oct. 14 at 7:47 PM

$CRVO it will never go back

0 · Reply

Shelz912 Oct. 14 at 7:13 PM

$CRVO This drug is an anti-inflammatory but not for arthritis but it has the potential. Maybe one day.

0 · Reply

BPler Oct. 14 at 5:29 PM

$CRVO

0 · Reply

Pharoh42 Oct. 13 at 9:24 PM

$CRVO I have now 10k shares with avg $10.24 Can we get there by earning?

1 · Reply

Doki0926 Oct. 13 at 7:11 PM

$CRVO WHAT WILL BE THE END FOR THIS FUCKING PIECE OF SHIT

1 · Reply

Disinformation_Consumer Oct. 10 at 8:24 PM

$CRVO lmao CRVO actually fell less than NVidia and Tesla today during trading hours. What a shitshow all around.

1 · Reply

Enzo4u Oct. 10 at 5:09 PM

$CRVO agreed, they will do some offering and tank this further

0 · Reply

Stu_padasso Oct. 10 at 5:01 PM

$CRVO fucking garbage

1 · Reply

Doki0926 Oct. 10 at 4:18 PM

$CRVO 😂😂😂😂

0 · Reply

BPler Oct. 10 at 3:22 PM

$CRVO After months of adding there is enough patience in me to wait to hear back from the FDA before Q4 ends. Know what you own. Even if they would need to raise more money it will be not at these market prices. They have warrants close to 40 USD waiting

1 · Reply

MV0527 Oct. 10 at 2:52 PM

$CRVO 9.00 by E.O.D.

1 · Reply

Pharoh42 Oct. 10 at 1:15 AM

$CRVO The number of watchers going down since the trial news This stock is getting weirder and weirder At this point all what I want to break even and move on.

1 · Reply

Doki0926 Oct. 9 at 8:57 PM

$CRVO piece of shit trust me

0 · Reply

BPler Oct. 9 at 5:59 PM

$CRVO "Together with other insights gained from Phase 2b, these results have enabled us to refine and optimize the design of our planned Phase 3 trial as we await FDA feedback later this quarter." https://www.neurologylive.com/view/neflamapimod-advances-phase-3-trial-dementia-with-lewy-bodies-after-positive-rewind-lb-results

0 · Reply

Enzo4u Oct. 9 at 5:25 PM

$CRVO have been warning you all

1 · Reply

Messerschmittbf109 Oct. 9 at 5:06 PM

$CRVO $SBET $JSPR coffee shop stocks Only vacuums

0 · Reply

BPler Oct. 9 at 4:57 PM

$CRVO Pure fuckery, adding

0 · Reply

Scorpole Oct. 9 at 4:26 PM

$CRVO Mist likely an offering is on the way

1 · Reply

Doom_Gloom_AR Oct. 9 at 3:55 PM

$CRVO Hopefully they bring this way the fuck down, under 6 - I'll eat all your fucking shares. GOBLE GOBLE mother fuckers. the drug works.

1 · Reply

CWL123 Oct. 9 at 1:39 PM

$CRVO back to 8 i guess

1 · Reply

ZenfireTrading Oct. 9 at 1:32 PM

$CRVO Never saw the follow through, but a winner is a winner. If you want to see the quant long/short side of the small cap market learn more at zenfiretrading.com/join ⚡✨

0 · Reply

Market Cap	75.41M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	46,080
Avg Vol	128,394
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	9%
Beta	-0.84
Analysts	Strong Sell
Price Target	$20.00